CD86 and melanoma: In melanoma mice, EXONeAgs increased the number of CD8+ and CD4+ T cells and activated DCs more efficiently, significantly up-regulated the DC activation marker proteins, CD80 and CD86, which further augmented the immune response, and triggered an efficacious antigen-specific immune response and tumor suppression.